Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
08 nov. 2023 08h00 HE
|
Aclarion, Inc.
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care....
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
06 nov. 2023 08h00 HE
|
Aclarion, Inc.
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian...
Aclarion Presents at the NIH HEAL Initiative Fall Meeting
01 nov. 2023 08h00 HE
|
Aclarion, Inc.
The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research. The Back Pain Consortium (BACPAC) Research Program, a...
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
25 oct. 2023 08h30 HE
|
Aclarion, Inc.
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George...
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
24 oct. 2023 08h45 HE
|
Aclarion, Inc.
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October...
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
23 oct. 2023 07h00 HE
|
Aclarion, Inc.
Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to...
Aclarion Provides Updated Investor Presentation and Corporate Update
02 oct. 2023 08h00 HE
|
Aclarion, Inc.
Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have formally engaged to partner with the company to drive market traction and...
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
25 août 2023 16h10 HE
|
Aclarion, Inc.
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI
14 juin 2023 11h27 HE
|
Aclarion, Inc.
BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
08 juin 2023 07h30 HE
|
Aclarion, Inc.
Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement...